Jun Yamamura

Dr. Jun Yamamura


Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2012 in Case Reports in Medicine
Verified
Journal Article
Open access
PDF file
JYJun Yamamura
Jun Yamamura
Norikazu MasudaNorikazu Masuda
Norikazu Masuda
YKYoshinori Kodama
Yoshinori Kodama
HYHiroyuki Yasojima
Hiroyuki Yasojima
MMMakiko Mizutani
Makiko Mizutani
MSMitsugu Sekimoto
Mitsugu Sekimoto
Carcinoma of an accessory mammary gland is an extremely rare tumor. A 61-year-old male patient presented with a hard mass measuring 85 mm × 51 mm in the left axilla. Incisional biopsy histopathologically showed an adenocarcinoma compatible with breast carcinoma originating in an accessory mammary gland. Systemic examinations revealed no evidence of malignant or occult primary lesion in the bilateral mammary glands or in other organs. Neoadjuvant chemotherapy was performed for the locally advanced axillary tumor and reduced the tumor to 55 mm in size, and, then, he could undergo complete resection with a negative surgical margin in combination with reconstructive surgery to fill the resulting skin defect with a local flap of the latissimus dorsi muscle. The patient has presented with no metastatic lesion in four years since the operation. This unusual case shows that neoadjuvant chemotherapy is an effective and tolerated therapy for advanced accessory breast cancer in the axilla.

1 March 2018 in In Vivo
Verified
Journal Article
Closed access
PDF file
JYJun Yamamura
Jun Yamamura
SKShunji Kamigaki
Shunji Kamigaki
JFJunya Fujita
Junya Fujita
HOHiroki Osato
Hiroki Osato
YKYoshifumi Komoike
Yoshifumi Komoike
Background/Aim: Patients with de novo stage IV and recurrent metastatic breast cancer are often treated with the same strategies, although the difference in prognostic outcomes remains unclear. The objective of this retrospective chart review study was to compare the prognostic outcomes between two types of patients with hormone receptor-positive (HR+), HER2-negative (HER2-) breast cancer. Patients and Methods: We estimated overall survival of the two groups and evaluated the progressive course of the disease using disease-free interval (DFI) and interval from the end of adjuvant treatment to the first recurrence (AFI). Results: We studied 172 patients with HR+/HER2-breast cancer, of which 65 were de novo and 107 were recurrent. Median OS between de novo and recurrent BC was 4.85 and 3.45 years, respectively (p=0.046). Recurrent patients with a DFI< 2 years were found to have a significantly poorer prognosis than recurrent patients with a DFI >= 2 years (p=0.016) and de novo patients (p=0.002). Similarly, recurrent patients with an AFI< 1 year had a significantly poorer prognosis compared to de novo patients (p=0.026). Conclusion: De novo patients had better prognoses than recurrent patients with DFI< 2 years or AFI< 1 year, likely due to their therapynaive status or lower resistance to systemic treatment.

1 October 2011 in The Breast
Verified
Journal Article
Open access
NFNoriko Fujita
Noriko Fujita
RKRyo Kimura
Ryo Kimura
JYJun Yamamura
Jun Yamamura
KAKenji Akazawa
Kenji Akazawa
TKTsutomu Kasugai
Tsutomu Kasugai
FTFumine Tsukamoto
Fumine Tsukamoto
We experienced a leiomyosarcoma of the breast in an 18-year-old female. No specific treatment has been established. In order to clarify appropriate therapeutic management methods, the limited data available from our and previous case reports were assessed. A leiomyosarcoma of the breast must be excised with a negative margin. If the tumor size is large and an adequate margin, greater than 3-cm margin around the excised tumor, is not achieved due to anatomical constraints, radiotherapy may be indicated.

26 December 2018 in In Vivo
Verified
Journal Article
Open access
PDF file
JYJun Yamamura
Jun Yamamura
SKShunji Kamigaki
Shunji Kamigaki
MTMasaki Tsujie
Masaki Tsujie
JFJunya Fujita
Junya Fujita
HOHiroki Osato
Hiroki Osato
YKYoshifumi Komoike
Yoshifumi Komoike
Background/Aim: Little evidence is currently available on significant determinants of post-recurrence survival for patients with hormone receptor-positive (HR+), HER2-negative (HER2−) breast cancer. The objective of this study was to evaluate factors influencing post-recurrence survival in HR+/HER2−breast cancer. Patients and Methods: A cohort of 236 patients with recurrent HR+/HER2− breast cancer was retrospectively analyzed to identify significant factors correlating with prognosis after recurrence. Results: Multivariate analysis revealed independent prognostic factors of poor survival as follows: short intervals between recurrence and the end of adjuvant endocrine therapy (ET; p=0.046); short disease-free intervals (p=0.019); liver metastasis (p=0.007) or multiple metastases (p<0.001) at recurrence; and a poor response to first-line treatment (p<0.001). A poor first-line treatment response was significantly associated with a shorter response to a subsequent treatment line (p=0.007). Logistic regression analysis indicated that liver metastasis significantly increased the risk of a poor first-line-ET response (p=0.009). Conclusion: The first-line treatment response was the key to post-recurrence survival in patients with HR+/HER2− breast cancer. Particularly poor responses led to subsequent unfavorable prognostic outcomes.

29 April 2021 in BMC Cancer
Verified
Journal Article
Open access
PDF file
JYJun Yamamura
Jun Yamamura
SKShunji Kamigaki
Shunji Kamigaki
JFJunya Fujita
Junya Fujita
HOHiroki Osato
Hiroki Osato
HMHironobu Manabe
Hironobu Manabe
YKYoshifumi Komoike
Yoshifumi Komoike
Background: The initial therapeutic strategy for hormone receptor-positive (HR+), HER2-negative (HER2-) breast cancer is based on the first metastatic site; however, little evidence is available regarding the influence of metastatic distribution patterns of first metastatic sites on prognosis. In this study, we aimed to identify the metastatic distribution patterns of first metastatic sites that significantly correlate with survival after recurrence. Methods: We performed a retrospective review of records from 271 patients with recurrent metastatic HR+/HER2- breast cancer diagnosed between January 2000 and December 2015. We assessed survival after recurrence according to the metastatic distribution patterns of the first metastatic sites and identified significant prognostic factors among patients with single and multiple metastases. Results: Prognosis was significantly better in patients with a single metastasis than in those with multiple metastases (median overall survival after recurrence: 5.86 years vs. 2.50 years, respectively, p < 0.001). No metastatic organ site with single metastasis was significantly associated with prognostic outcome, although single metastasis with diffuse lesions was an independent risk factor for worse prognosis (HR: 3.641; 95% CI: 1.856–7.141) and more easily progressing to multiple metastases (p = 0.002). Multiple metastases, including liver metastasis (HR: 3.145; 95% CI: 1.802–5.495) or brain metastasis (HR: 3.289; 95% CI: 1.355–7.937), were regarded as significant independent poor prognostic factors; however, multiple metastases not involving liver or brain metastasis were not significantly related to prognosis after recurrence. Conclusions: Single metastases with diffuse lesions could more easily disseminate systemically and progress to multiple metastases, leading to a poor prognosis similar to multiple metastases. Our findings indicate that the reconsideration of the determinant factors of therapeutic strategies for first recurrence in HR+/HER2- breast cancer may be needed.

10 December 2019 in Japanese Journal of Clinical Oncology
Verified
Journal Article
Open access
PDF file
TUTakayuki Ueno
Takayuki Ueno
Norikazu MasudaNorikazu Masuda
Norikazu Masuda
NSNobuaki Sato
Nobuaki Sato
SOShoichiro Ohtani
Shoichiro Ohtani
JYJun Yamamura
Jun Yamamura
MTMasakazu Toi
Masakazu Toi
The original aim of this study was to evaluate the treatment sequence and anthracycline requirement in docetaxel, cyclophosphamide and trastuzumab therapy. After one death in the anthracycline-containing arm, the protocol was amended to terminate the randomization. The single-docetaxel, cyclophosphamide and trastuzumab arm was continued to examine the efficacy and safety of the anthracycline-free regimen. Women with human epidermal growth factor receptor-2-positive, operable and primary breast cancer were randomized to receive 5-fluorouracil, epirubicin and cyclophosphamide (four cycles) followed by docetaxel, cyclophosphamide and trastuzumab (four cycles), or docetaxel, cyclophosphamide and trastuzumab followed by 5-fluorouracil, epirubicin and cyclophosphamide, or docetaxel, cyclophosphamide and trastuzumab (six cycles). After the protocol amendment, patients were allocated to the docetaxel, cyclophosphamide and trastuzumab arm alone. The primary endpoint was a pathological complete response. In total, 103 patients were enrolled between September 2009 and September 2011: 21, 22 and 24 patients in the 5-fluorouracil, epirubicin and cyclophosphamide followed by docetaxel, cyclophosphamide and trastuzumab; docetaxel, cyclophosphamide and trastuzumab followed by 5-fluorouracil, epirubicin and cyclophosphamide and docetaxel, cyclophosphamide and trastuzumab arms, respectively, and 36 patients in the docetaxel, cyclophosphamide and trastuzumab arm after the protocol amendment. In total, 60 patients were allocated to the docetaxel, cyclophosphamide and trastuzumab arm, in which the pathological complete response rate was 45.8%, and disease-free survival at 3 years was 96.6%. Patients with stage I or IIA in the docetaxel, cyclophosphamide and trastuzumab arm showed good disease-free survival (100% at 3 years). The comparison of efficacy among the three arms was statistically underpowered. Left ventricular ejection fraction decreased significantly after 5-fluorouracil, epirubicin and cyclophosphamide followed by docetaxel–docetaxel, cyclophosphamide and trastuzumab (P = 0.017), but not after docetaxel, cyclophosphamide and trastuzumab followed by 5-fluorouracil, epirubicin and cyclophosphamide or docetaxel, cyclophosphamide and trastuzumab. The pathological complete response rate for docetaxel, cyclophosphamide and trastuzumab was similar to previous reports of anthracycline-containing regimens. Docetaxel, cyclophosphamide and trastuzumab might be an option for primary systemic therapy in human epidermal growth factor receptor-2-positive early breast cancer. A larger confirmatory study is necessary.